VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Dengue Virus DNA Vaccine expressing prM/E proteins
Vaccine Information
  • Vaccine Name: Dengue Virus DNA Vaccine expressing prM/E proteins
  • Target Pathogen: Dengue Virus
  • Target Disease: Dengue Fever
  • Vaccine Ontology ID: VO_0004547
  • Type: DNA vaccine
  • Status: Research
  • Antigen: prM and E proteins from dengue virus 4 strain H241 (Lima et al., 2011)
  • prM from Dengue virus 4 gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • E from Dengue virus 4 gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000212
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: Ten 5-week-old female BALB/c mice per immunization group were inoculated three times into the quadriceps muscle with 100 μg of DENV-4-DNAv or pCI (empty vector), DENV-4 heat inactivated (1 × 10^5 PFU), or PBS. The mice were primed on day 0 and boosted 15 and 30 days after the initial inoculation (Lima et al., 2011).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: The animals immunized with DENV-4-DNAv produced rising levels, after each vaccine inoculation, of specific neutralizing antibodies against dengue-4 virus (Lima et al., 2011).
  • Challenge Protocol: Fifteen days after the third inoculation, the mice were challenged intracerebrally with a dose of 100LD50, prepared from a DENV-4-infected suckling mouse brain. Mouse mortality was monitored daily for 21 days (Lima et al., 2011).
  • Efficacy: Immunization with DENV-4-DNAv induced significant protection against DENV-4 challenge, where 80% of the challenged mice survived (Lima et al., 2011).
References
Lima et al., 2011: Lima DM, de Paula SO, França RF, Palma PV, Morais FR, Gomes-Ruiz AC, de Aquino MT, da Fonseca BA. A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine. 2011; 29(4); 831-838. [PubMed: 21115054].